共 151 条
[1]
Burstein HJ(2019)Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update J Clin Oncol 37 423-438
[2]
Lacchetti C(2016)Extending aromatase-inhibitor adjuvant therapy to 10 years N Engl J Med 375 209-219
[3]
Anderson H(2008)Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy Breast Cancer Res Treat 107 167-180
[4]
Buchholz TA(2010)Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients J Clin Oncol 28 4120-4128
[5]
Davidson NE(2012)High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial Eur J Surg Oncol 38 110-117
[6]
Gelmon KA(2003)Aromatase inhibitors in breast cancer N Engl J Med 348 2431-2442
[7]
Giordano SH(2002)Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 751-757
[8]
Hudis CA(2008)Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer J Clin Oncol 26 1671-1676
[9]
Solky AJ(2021)Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial Breast Cancer Res Treat 187 769-775
[10]
Stearns V(2022)Sex steroid hormone analysis in human tear fluid using a liquid chromatography—mass spectrometry method Int J Mol Sci 23 14864-2263